Conditions: Neutrophilic Asthma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 37
Healthy volunteers: no

Brief summary:
4-Week Safety Study in Subjects with Neutrophilic Asthma

Detailed description:
Effect of treatment with navarixin (MK-7123, SCH 527123) on sputum neutrophils and asthma symptoms

Arms:
arm 1: Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks arm 2: Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks

Interventions: intervention 1: Navarixin intervention 2: Placebo intervention 3: Rescue medication
Intervention descriptions: intervention 1: Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks. intervention 2: Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks. intervention 3: Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms

Protocol document: